External Research Collaborations | Academic Partnerships & External Innovation• Interface with universities and academic research institutions in support of external innovation goals; provide guidance and updates to internal stakeholders regarding key transactions • Discuss research plans and requirements with Biomedical Research scientists; work with Novartis legal and IP attorneys to structure appropriate agreement terms; interface with finance and operations• Negotiate, draft, and execute variety of contracts with academic institutions, including research collaborations, technology licenses, material transfer agreements (MTAs), confidential disclosure agreements (CDAs), consulting, visiting scientist, and consortium agreements

• Managed team of technology licensing professionals that oversee intellectual property, industry-sponsored research collaborations, and licensing across Mass General Brigham’s Neurology, Neurosurgery and Internal Medicine (ID, Renal, Endocrine) departments; technology assets span multiple therapeutic areas and modalities, including gene and cell therapy, oncolytic virus, small molecule, antibody, peptide, and other biologics, as well as medical devices, diagnostics, and research tools• Negotiated financial and contract terms for intellectual property assets, including patents, copyrights, and research materials; contracts include options, exclusive and non-exclusive licenses to technology assets in portfolio with biopharma and MGB spin-out companies• Negotiated contract terms for research collaborations with multiple biopharma partners; executed and managed industry-sponsored research contracts totaling ~$50M to MGB between 2016 - 2021Licensing and contracts | Term sheet negotiation | Intellectual Property management | Invention and technology evaluation | Technology transfer

Manage the medical technology portfolio (medical devices, therapeutics, drug delivery platforms, diagnostics, medical imaging, and life science research tools) of Boston University and Boston Medical Center.

Mid-sized pharmaceutical company with focus on anemia and imaging agentsEvaluated out-licensing deal terms and profitability of imaging agent to AMAG in order to guide effective negotiating strategies with partners.

Boutique strategy consulting and venture capital firm focused on healthcare and high technology• Conducted multiple strategic marketing projects on behalf of clients evaluating growth opportunities in the healthcare industry: market size, receptivity and adoption of new medical technologies • Utilized qualitative and quantitative market research methods to understand clinical practice patterns, trade-offs among competing therapies, and clinical adoption of new technologies;• Analyzed epidemiology, medical/scientific literature, and financial data to construct market models forecasting penetration and sales of new healthcare products for clients• Analyzed potential acquisitions and performed due diligence on healthcare companies for clients• Analyzed healthcare companies to support investment by one of FSV’s two fundsAnalyzed emerging medical device, diagnostic, and biotech companies to support investment by FSV and other risk-capital investors.Strategic Market Research | Qualitative interviews with KOLs, clinicians, and scientists | Quantitative research | Market and product forecasts | Acquisition due diligence | Venture capital investment

Maintained independent research project in laboratory of 30+ scientists and staff. Collaborated with scientists to optimize protocols. Project resulted in three scientific publications.